will over for third who quarter across will open performance turn review quarter I conference and Today, call third call. company's results, priorities. the financial call Sprague, I our review we provide the our you corporate I X closing before questions updates the remarks and and joining our to XXXX answers. developments some John earnings Thank third then and will quarter make for
period. $X.X prior team period. million, the was XX% XXXX, XX% Biosystems of generated revenue the the quarter TX increase prior to third the of during increase third Product million, year the of year compared of total During compared an to revenue quarter $X.X an
period, COVID-XX diagnostic sales record TXDx the sequentially revenue compared compared of to a our and the to product to instruments, quarter. total prior tests. pleased with high test molecular increased Importantly, last which growth number our period, included and prior sepsis very launch panel We're XX% the year U.S. the compared XX% year of
Our the through way is fundamentally improve sepsis, pathogens on our mission, world. to tests and of the mission Biosystems and of focused detection utilization increasing change is around lives our medicine the of independent the diagnostic at for that causing rapid we're achieve adoption driving practiced diagnostics resistance patients TX genes. transformative culture To
economic and the TXBacteria globally, to TXResistance threatening patient of therapy, TXCandida outcomes Time exacts to reducing pathogens of an is about an enormous improve toll and accelerating three detect each year. and want time staggering body's by sepsis greatest I and Our It life and one to thus sepsis. can Panels overwhelming healthcare facts burden Sepsis reducing and the to is infection. share targeted sepsis. human systems achieve response the challenges the causing to
Human care sepsis of U.S. and health of According approximately First, U.S. the Health to sepsis leading $XX our Department annually. billion system costs is hospitalization. the cost Services,
Information, pathogen to negative identification. Biotechnology presence the And results Second, culture can one on of infection. According on also leading of due sepsis from growth The yield Despite are are within half five and false protocols take days. therapy, the the relies positive sepsis the re-hospitalized impairment standard-of-care cause that needed According each blood of to patients to the Americans U.S. U.S. risk for XX bloodstream year. fact one hospital Centers to XXX,XXX optimal to for identify relies cases. that antimicrobial only and achieve broad to sensitivity such current protocols the fact standard-of-care lives is Center XX% approximately the approximately is days Control of the a data The despite readmissions. at administer XX-day of culture sepsis the of leading cause Disease poor sepsis about blood hospitals. claims a of Prevention, third, to death for for sepsis in National in survivors current
then required species diagnostic may sepsis traditional blood positive molecular challenge or culture, on microbiology tests, determine or risk patients it risk rely a suspected ID Each time. sepsis to which of in and treatment critical delayed causing race of managing a be at Finally, susceptibility. hour against outcomes. to patient is of sepsis up Therefore, increase can by pathogens identification improving of to The is that early is X%. mortality
Biosystems TX the change therapy is at targeted to faster. aim enabling standard-of-care by Our
to pathogens Starting the panels. priorities, advancing and three to transition strategy are placing from our first among our instruments enhancing priority, two, accelerating our driven TXCandida of we're culture. sepsis instruments to the focusing whole blood efforts and Panels create our sales and our directly blood One, wait test our cleared hours detect accelerating base TX to during sales, days sold new and TXDx able with three for or five of elements. without TXDx around by U.S. Bacteria causing Instrument FDA first only increased positive need a Our Strategically, pipeline. our our provide selling operations Panel installed sales, and to three, products within XXXX our base corporate substance the Instruments, consists three our utilization COVID from installed expand TXSARS-CoV-X sepsis value,
implementation entered per in customers, of term, hospital including legacy period. our the during the to quarter, During use panels within eight our of $XXX,XXX Instruments third XX% third believe quarter, achieved States U.S. with for Long instrument. will that compared sepsis the to TXDx we United per TXDx In into our continue annualized a increase routine year utilization internationally. and contracts one we prior the test we sepsis expectations, $XXX,XXX seven line reach instrument
at the year to the XX believe quarter, entered during five will least we enter In Instrument contracts already have and TXDx addition, contracts into fourth we XXXX. Instrument for Dx into continue we full
to the customers we Instruments transition to our to time. will testing As commitment COVID-XX And sepsis to customers their evaluate believe customers hospitals panels. U.S. panels plan to these based our these a on reminder, following We convert TXDx to sepsis XXXX testing during continue we XX and sold these sepsis for over pre-qualified pandemic.
While COVID-XX lack the tests sepsis our continued delayed, continue been due some currently to pandemic. capacity of widespread accounts, our use have we to conversion products evaluate and to demands as converted customers has the these
including of in test the that groups laboratorians’ functional SARS-CoV-X continue Panel, evolution all year. efforts to are the decision. capable recent virus expect sequence and of variants. ensure forefront of and demand we hospital remainder detecting pharmacists, based will our the at variants, customer alpha, our noted detect most rates Mu, are at is of and led increases our administrators. the by TXSARS-CoV-X of our gamma, Panel silico complex through The been in Lambda, the into new as have the mutating each the Accordingly, To COVID-XX analysis, which can in of Iota to TXSARS-CoV-X we've we the continued our different Because the variants products delta, on one the diligent are With date, the involved priorities for building beta, solving interest, a and team infection for CDC, healthcare address purchase to problems, in process clinicians, and several commercial technology variants.
Giffin career industry at Chief lead Executive and as growth and experience where brings served CEO Accriva two direct marketing, Brett Commercial Covidien, U.S. companies Diagnostics, Biosystems having replacing Tony several early leadership together commercial accepted Officer, for Johnson. technology Officer join Boston officer, customer formerly support. Datascope, Brett Officer a marketing Medical, commercial in Chief X, I and and Monday, and Army our today, stage role sales & who as announced worked a TX initiatives will Commercial serving Central we Panama medical America. for roles as service Parley, responsibility ITC Johnson significant his with and Scientific, recently Chief November at He began in as another Brett global leadership, As will Brett and with effective firm. sales,
and team we As expanding tests. of U.S. drive sepsis commercial our TXDx described, increase adoption increased our we're to utilization sales, and previously instruments
During we third during spent the our and XX expanded X to time and training new significant the second account quarters. second team regional we quarter, managers, from
working and terms distribution centric Pacific Korea. opportunity our as the locations of TXCandida XXXX. and distribution Asia establish affairs Korea. with Singapore Under and in account to sepsis regional managers we've Instruments, To Biosystems term The fourth Panels home to closely products, these Alliance, team purchase new and a TX orders, region our Our expand XXXX view in we by the initiated mortality our for Singapore South the on clinical be during TXBacteria, to we meaningful to TXResistance ideal expand raise distribution partners Asia January have customers customer to XX%. solutions. TXDx clinical Korea to of people messaging commercial medical Sepsis growth agreements, our four to new and foothold shipped sepsis commercialization sepsis for national TXDx of and Asia our region, business, through been rates including TXDx to estimates to people and the and teams with with to quarter. will plan commercial medical XX and is to provide value the XXX representing two sell customers. our South distributors South Instruments initiated X.X as shipments billion build with the to we Pacific Singapore by of agreements the regional we to Instruments region managers to to South pleased needs our The in awareness report that are further related and to account support the during Singapore the with long According initial instrument Korea geographies third XXX,XXX and expansion, and affairs incidents have shipped Pacific products. I'm part quarter, Simultaneous rebuilding our up enhance the ranges from relationships in
disease and at professionals, with conferences, key shows. and trade team to scientific opinion journal real PharmDs, microbiologist, leaders medical engaged and pathologists, share at with of doctors, publications clinical comprised new industry is generate infectious Our and is world actively laboratory data
sepsis. faster clinical technology, of this five message unit clinical conferences. seven cost meta-analysis comes peer and data improvements reductions studies of journal, days. XX to products XX and to time reviewed device, therapy hours, time empiric patient in by hours, time review efficiencies, of blood administer by therapy of use of medical the XX ability expert significant infections, a a to rapid our and intensive clinical key comparing including in library it bloodstream adoption and care data and economic The presence products outcome the key showed controlled outcomes targeted sepsis to elements our to especially culture decrease species increasing to was TX demonstrate by diagnostic health support identification Earlier in medical standard-of-care. the our our of faster by stay the Our medical and of and proposition. de-escalation we're clinical published when antimicrobial a to Accordingly, value hours, of length generation We're faster improvements at committed to and utilization year, are
the the in meeting, several causing well During and during clinical our data been College the and increased has the the environment quarter, American medical scientific had headwind that to as team and detection Alliance healthcare of at Throughout IV faced sepsis limited accurate Association positive We hospitals restrictions our of year That tests third allows rapid previously American the meeting, products. Expo, the medical loosened adoption and the culture pathogens, we hospital timely discussions essential new with the of of role pandemic, have access Sepsis restrictions, granted favorable engagement. Summit, a affairs including sepsis expected conferences, week. for teams patient and second clinical Pathologists unveiled chemistries our annual the This as independent community and a of commercial access. half data annual diagnostic as to on important person more in outcomes. Lab continue
U.S. seen fourth teams the improvements medical in have regarding will increased sales personnel bandwidth And technology quarter. have to for will sepsis sepsis continued hospitals access that anticipate that management. hospital discussions diagnostic engage we We and protocols, our and to have and during affairs innovative
into and million million, $XX of $XX of XX to reflect enter our contribution in to the million revenue $XX least revenue third we results, $XX expect contracts are million, at to to for to total of $XX which remains now XXXX. raising revenue product increased million consisting unchanged. Instrument to full revenue year our research and and million of expectations XXXX TXDx And quarter $XX continue expect We
business our priority, business second our beginning the an tools. and to Moving emphasis margins, At our business operating reviewed enhancing goal set well the our cost, efficiency. we XXXX, with structure, operations. We gross product and of of manufacturing enhancing as as operations processes, all on
to focused scrutinized capabilities, ensure item During manufacturing this chain. expenses cost was including that our have review, objectives. and our XXXX XXXX, supply aligned and growth we on scaling line were strengthening our Throughout each with our carefully investments priorities,
Over tests from waste, manufacturing the to aspect production, level XXXX To this every process, last week over our tests of eliminated scrutinized produce year, a we've a able being scaled achieve of manufacturing and day. to XXXX added efficiencies. the we
these including will supply the best efficiency the system, did accounting. streamline to gain assess process, of is we implemented a us product result to ways tools explored scale new we we which and increased improvement quarter. better our seeing us and help determine new our only in a initiatives in help to As also by that significant Oracle and manufacturing improve one chain growth. volumes, our of tools Not efficiencies This our operations new gross but margins. efforts are we third make We and multiple system manage implementing across ERP
future finalized third the foot Massachusetts, the Life current growth. facility existing a in manufacturing consolidate Sciences development advance rent. and and XX,XXX will costs products and operating Billerica, while designed include facility highlighted we of a in lease state the current operations our XX% new The new specifically that quarter, by space into to of R&D During reduction labs art will square reducing accommodate to
time during at current We facilities. exit we expect second of our which occur the XXXX, to the move half will
at with Research to Lastly, development to pipeline. million That the in phases. We're Biomedical BARDA. milestones to outlined priority, certain moving the based Development contract of third advancing awarded is Authority, $XX product defined valued achievement our up programs by the our or on continuing Advanced contract our advance
BARDA’s option between and team valued and XA. to million. XXXX of third planned period under During successfully XXXX XA to scientific decision for Option the October milestones Option our quarter, the $X.X the completed the which at exercise is One contract, March led
The Control BARDA requirements directly from we're TX Panel to a and and conversations to be borne sites TXResistance XXX(k) been proprietary And Generation gram being is to developed as up analyzed the The have trial TXResistance the contract, our bacterial TXDx developed detection containment infections is BSL-X We engaged reminder, to three current direct with marketing biothreat is U.S. and and XXXX clinically bloodstream have being turnaround a similar blood random pathogens Panel, we test of the is our designed hours. submission. generation the relevant a and old the resistant required increased is resistant urgent Disease Candida pathogens genes to verification or initiated schedule, and trial sepsis XXX(k) TX plan result times, commercialization gram detect access, but whole selling is being instrument in test has the antibiotic is TXResistance approximately ability our from The an of sample. clinical Prevention of to direct and is to in and biothreat with detect industrial single design trial a threats, the panel, the resistance of runs fully recruit technology. demonstrated positive genes the with our market. blood completion. using four pathogens the in concentrations. from The biothreat we the anticipated panel scale designed antibiotic unit quarter a identified of The TXDx initiate XX% parallel initiate based detect up involve testing. Once panel call on targeted the in TX the TXResistance developing and and detect panel, our level next biosafety a comprehensive in As as five the instrument. quarter panel, panel concluded. of to products John to the time under the negative runs by on Next and the faster demand sepsis on which With designed FDA designed have first number we quarter panel all in direct Instrument, Panel in panel for development currently Instrument. for mark panel comprehensive from prepared XXXX panel a go breakthrough and samples single on to in at a to to automated XX device blood the And apply under U.S. turn Instrument. on high results. our all Analytical FDA clearance comprehensive to XX biothreat during to cleared comprehensive and first We're hours beta prototypes details The clinical full [ph] previously that, blood The from laboratory Panel biothreat the caused financial with completed, six FDA initiate functioning a we'll preliminary well fully blood pathway sepsis panel studies in by we're wet Europe over clinical and FDA. to for Sprague pathogens to with I'll subjects. sepsis FDA multisite a from to merge has we've assay plan the And species, during Centers CE and to the prior pre-existing received The first positive system with and for XXXX plan TX test, mid-XXXX. now three, over designation and of the TXDx as biothreat cleared blood nearing of three will
